SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Dahl Andrew M. | SVP, Corporate Controller | 2026-08-31 | Open-market sell | 544 | $50K |
| Bruls Annette | CVP, EMEACLA | 2026-08-28 | Open-market sell | 2644 | $238K |
| Chopra Daveen | CVP, TMTT, Surgical & IHFM | 2026-08-26 | Option exercise | 31800 | $2.3M |
| Chopra Daveen | CVP, TMTT, Surgical & IHFM | 2026-08-26 | Open-market sell | 1154 | $106K |
| Chopra Daveen | CVP, TMTT, Surgical & IHFM | 2026-08-26 | Open-market sell | 30646 | $2.8M |
| Markowitz Wayne | CVP, JAPAC | 2026-08-26 | Open-market sell | 1240 | $113K |
| Lippis Daniel J. | CVP, TAVR | 2026-08-11 | Option exercise 10b5-1 | 619 | $45K |
| Lippis Daniel J. | CVP, TAVR | 2026-08-11 | Open-market sell 10b5-1 | 619 | $57K |
| Markowitz Wayne | CVP, JAPAC | 2026-07-30 | Open-market sell | 146 | $13K |
| Markowitz Wayne | CVP, JAPAC | 2026-07-28 | Option exercise | 9628 | $713K |
| Markowitz Wayne | CVP, JAPAC | 2026-07-28 | Open-market sell | 9628 | $819K |
| Zovighian Bernard J | CEO, Director | 2026-07-27 | Gift | 320 | $0 |
| Zovighian Bernard J | CEO, Director | 2026-07-27 | Gift | 320 | $0 |
| Zovighian Bernard J | CEO, Director | 2026-07-27 | Open-market sell | 2921 | $245K |
| Bruls Annette | CVP, EMEACLA | 2026-07-11 | Tax withholding | 109 | $10K |
| Lippis Daniel J. | CVP, TAVR | 2026-07-10 | Option exercise 10b5-1 | 619 | $45K |
| Lippis Daniel J. | CVP, TAVR | 2026-07-10 | Open-market sell 10b5-1 | 619 | $57K |
| Mistras Theodora | CVP, Chief Financial Officer | 2026-07-09 | Grant/award | 87595 | $0 |
| Mistras Theodora | CVP, Chief Financial Officer | 2026-07-09 | Grant/award | 12325 | $0 |
| Lippis Daniel J. | CVP, TAVR | 2026-07-07 | Tax withholding | 377 | $36K |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
Edwards Lifesciences' risk profile has broadened and concretely worsened across multiple fronts, with commercialization headwinds now explicitly tied to real operational constraints and self-competition from its own TAVR/TMTT portfolio. Tariff exposure, hospital staffing shortages, and catheterization lab availability have been newly specified as material impediments to revenue, while post-acquisition liabilities and divestiture disputes add a fresh litigation and reputational dimension. No single existential risk is present, but the worsening is substantive and spans four distinct themes.
4 company-specific · 2 common-mode
Added specific operational constraints: U.S. national coverage determination restrictions, hospital staffing shortages, and catheterization lab availability. These are concrete, material impediments to product commercialization.
Business and Operating Risks Failure to successfully innovate and develop new and differentiated products in a timely manner and effectively market these products could have a material effect on our…
New disclosure of constrained procedure volumes and sales due to intensified intra-hospital competition, including from Edwards' own products. Indicates worsening competitive pressure and revenue headwinds.
We operate in highly competitive markets, and if we do not compete effectively, our business will be harmed. We face substantial competition and compete with technologies of many types and companies…
Added specific internal competitive threat (own TAVR/TMTT products) and explicit past/future revenue impact language, escalating hospital facility competition risk.
The success of many of our products depends upon certain key physicians, research institutions, and hospital systems. We work with leading global physicians and research institutions who provide…
Added explicit disclosure of post-acquisition liabilities, litigation risks, and divestiture disputes with reputational harm—substantive new risk categories not previously disclosed.
Failure to successfully integrate acquired businesses, technologies or strategic alliances, or challenges related to the execution of acquisitions or divestitures, as well as liabilities or claims…
Added specific, current tariff risks: Section 232 investigation, dynamic 2025 tariff environment, concrete impact scenarios (manufacturing costs, supply chain disruption, margin pressure).
Our international operations subject us to certain business risks. We are from time to time impacted by a variety of risks associated with doing business internationally that can harm our future…
Added specific risk of FDA delays from government shutdowns and expanded ESG/environmental regulatory compliance burden with cost implications.
We and our customers are subject to healthcare legislation and other rigorous governmental regulations and we may incur significant expenses to comply with these regulations. In addition, failure to…
Edwards Lifesciences issued a press release on July 23, 2026 disclosing second quarter 2026 financial results, including Q2 sales of $1.74 billion (13.6% growth), Q2 EPS of $0.42 (adjusted $0.78), and updated 2026 full-year guidance. The filing is structured as Item 2.02 with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes detailed segment performance (TAVR, TMTT, Surgical), margin analysis, and forward guidance.
View raw filing on EDGAR →